Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target Cut to $5.00 by Analysts at Bank of America

Perspective Therapeutics (NYSEAMERICAN:CATX) had its price target decreased by Bank of America from $6.00 to $5.00 in a research report report published on Friday,Benzinga reports. Bank of America currently has a neutral rating on the stock.

A number of other equities research analysts have also recently weighed in on CATX. Wedbush restated an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research note on Tuesday, May 5th. BTIG Research reiterated a “buy” rating on shares of Perspective Therapeutics in a report on Friday, July 24th. Finally, Piper Sandler dropped their target price on Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating on the stock in a report on Tuesday. Eight investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.56.

Perspective Therapeutics Price Performance

Perspective Therapeutics stock opened at $3.20 on Friday. Perspective Therapeutics has a 52-week low of $1.96 and a 52-week high of $6.16. The firm has a 50-day moving average price of $3.08 and a two-hundred day moving average price of $3.94.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.03. Perspective Therapeutics had a negative net margin of 28,467.97% and a negative return on equity of 41.92%. The company had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.09 million. Sell-side analysts anticipate that Perspective Therapeutics will post -1.05 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Aigen Investment Management LP purchased a new stake in shares of Perspective Therapeutics in the fourth quarter worth approximately $28,000. Russell Investments Group Ltd. grew its position in Perspective Therapeutics by 184.1% during the third quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock valued at $29,000 after purchasing an additional 5,475 shares in the last quarter. nVerses Capital LLC acquired a new position in Perspective Therapeutics in the 4th quarter valued at approximately $31,000. AXQ Capital LP lifted its position in Perspective Therapeutics by 24.2% in the 4th quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock worth $35,000 after buying an additional 2,481 shares in the last quarter. Finally, Engineers Gate Manager LP purchased a new stake in Perspective Therapeutics in the 4th quarter worth approximately $35,000. 54.66% of the stock is owned by institutional investors and hedge funds.

Key Perspective Therapeutics News

Here are the key news stories impacting Perspective Therapeutics this week:

• Positive Sentiment: Improved 2026 earnings outlook: Brookline Capital Markets raised its FY2026 EPS forecast to a loss of $0.99 from a loss of $1.23. It also narrowed expected losses for Q3 2026 to $0.25 per share from $0.32 and for Q4 2026 to $0.26 from $0.36, indicating better-than-previously-expected cost or operating performance. MarketBeat analyst estimates
• Neutral Sentiment: Mixed analyst stance: Bank of America lowered its price target from $6 to $5 while maintaining a “neutral” rating. The revised target still implies substantial potential upside from recent trading levels, but the reduction signals more cautious expectations for Perspective Therapeutics. Benzinga analyst update
• Neutral Sentiment: Continued projected losses: Brookline expects Perspective Therapeutics to remain unprofitable, forecasting losses of $0.26, $0.27 and $0.30 per share in the first three quarters of 2027 and a full-year 2027 loss of $1.14 per share. These estimates underscore the company’s ongoing need to fund development while advancing its pipeline. MarketBeat 2027 earnings estimates
• Negative Sentiment: Piper Sandler lowered its expectations for CATX: The analyst revision adds to a more cautious valuation backdrop, although specific changes to the price target or rating were not provided in the available report. Piper Sandler expectations update

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.